Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

This article was originally published in PharmAsia News

Executive Summary

India's National Pharmaceutical Pricing Authority has imposed a 15-day deadline on 11 drug manufacturers to rein in costs of certain drugs, citing the "public interest" of lower prices for consumers

You may also be interested in...



IP Protection Concerns Grow In India, PhRMA Says

Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America

IP Protection Concerns Grow In India, PhRMA Says

Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America

Indian Court Hands Novartis Setback In Gleevec Patent Case

Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.

Related Content

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel